KUALA LUMPUR (Feb 26): Duopharma Biotech Bhd (KL:DPHARMA) saw its net profit for the latest fiscal year rise to a new record high on the back of resilient demand, complemented by a one-off surge in insulin supply in the first half.

Net profit for the year ended Dec 31, 2025 (FY2025) climbed 39.6% to RM87.46 million — its highest annual net profit on record — from RM62.65 million in the previous year, according to the drugmaker’s bourse filing on Thursday.

Resilient demand from both the public and private sectors across all business segments drove a 14.5% growth in revenue to a record RM931.69 million from RM813.67 million in FY2024.

Quarterly, Duopharma also closed the fiscal year with a resilient final quarter. Net profit for the three months ended Dec 31, 2025 (4QFY2025) rose 26.3% to RM19.05 million from RM15.08 million a year earlier, as revenue increased 16% to RM224.69 million from RM193.67 million.

The group declared a second interim dividend of 3.05 sen per share, payable on March 30.

Looking ahead, Duopharma said increased healthcare funding under Budget 2026, together with the focus on improving pharmaceutical research and manufacturing for a strong supply chain under the 13th Malaysia Plan, offer the group potential to strengthen its position as a leading domestic pharmaceutical player.

“Looking ahead, the new leadership at Duopharma will remain proactively focused on enhancing operational efficiencies, optimising cost management strategies, and executing strategic initiatives,” said Duopharma group CEO Wan Amir-Jeffery Wan Abdul Majid.

Shares in Duopharma ended two sen or 1.38% higher at RM1.47, valuing the group at RM1.41 billion.